Pretreatment Neutrophil-to-Lymphocyte Ratio as an Independent Predictor of Recurrence in Patients With Nonmetastatic Renal Cell Carcinoma
Abstract
Purpose:
We investigated the prognostic significance of the neutrophil-to-lymphocyte ratio to predict recurrence in patients with nonmetastatic renal cell carcinoma.
Materials and Methods:
We retrospectively reviewed the records of 192 patients with nonmetastatic renal cell carcinoma (T1-4N0M0) who underwent nephrectomy between 1986 and 2000. Mean followup was 93 months (range 6 to 232) months. We assessed the prognostic value of the pretreatment neutrophil-to-lymphocyte ratio, and other clinical and laboratory parameters on univariate and multivariate analysis.
Results:
Presentation mode, tumor stage, C-reactive protein, lymphocyte count and the neutrophil-to-lymphocyte ratio significantly correlated with recurrence-free survival on univariate analysis. The recurrence-free survival rate in patients with a neutrophil-to-lymphocyte ratio of less than 2.7 was 93.7% at 5 years and 79.8% at 10 years, significantly higher than the 77.9% and 58.4%, respectively, in patients with a ratio of 2.7 or greater (p = 0.0205). Multivariate analysis revealed that T stage and the neutrophil-to-lymphocyte ratio were independent predictors of recurrence. The 10-year survival rate in patients at low risk (T2 or less and neutrophil-to-lymphocyte ratio less than 2.7), intermediate risk (T2 or less and ratio 2.7 or greater, or T3 or greater and ratio less than 2.7) and high risk (T3 or greater and ratio 2.7 or greater) was 82.0%, 63.6% and 33.0%, respectively, which were significantly different.
Conclusions:
An increased pretreatment neutrophil-to-lymphocyte ratio is an independent predictor of recurrence. The combination of T stage and the neutrophil-to-lymphocyte ratio can be used to stratify recurrence risk in patients with nonmetastatic renal cell carcinoma.
References
- 1 : Cancer statistics, 2004. CA Cancer J Clin2004; 54: 8. Google Scholar
- 2 : Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am2003; 30: 843. Google Scholar
- 3 : Prognostic factors in renal cell carcinoma. Semin Oncol2006; 33: 563. Google Scholar
- 4 : Cancer-related inflammation. Nature2008; 454: 436. Google Scholar
- 5 : C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J Urol2005; 173: 52. Link, Google Scholar
- 6 : Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int2007; 99: 77. Google Scholar
- 7 : Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg2003; 90: 215. Google Scholar
- 8 : Correlates of circulating C-reactive protein and serum amyloid A concentrations in breast cancer survivors. Breast Cancer Res Treat2009; 114: 155. Google Scholar
- 9 : Ratio of neutrophil to lymphocyte counts—rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy2001; 102: 5. Google Scholar
- 10 : Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol2005; 91: 181. Google Scholar
- 11 : The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology2007; 73: 215. Google Scholar
- 12 : Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother2009; 58: 15. Google Scholar
- 13 : TNM staging of renal cell carcinoma: Workgroup No. 3: Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer1997; 80: 992. Google Scholar
- 14 : Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer2003; 88: 348. Google Scholar
- 15 : Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy. Cancer1997; 79: 952. Google Scholar
- 16 : Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur Urol2009; 55: 1145. Google Scholar
- 17 : Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy. J Immunother2003; 26: 394. Google Scholar
- 18 : Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol2009; 16: 614. Google Scholar
- 19 : Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg2008; 32: 1757. Google Scholar
- 20 : Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg2009; 137: 425. Google Scholar
- 21 : The ratio of neutrophils to lymphocytes and the phenotypes of neutrophils in patients with early gastric cancer. J Cancer Res Clin Oncol1998; 124: 329. Google Scholar
- 22 : A preoperative clinical prognostic model for non-metastatic renal cell carcinoma. BJU Int2003; 92: 901. Google Scholar
- 23 : An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol2002; 168: 2395. Link, Google Scholar
- 24 : A postoperative prognostic nomogram for renal cell carcinoma. J Urol2001; 166: 63. Link, Google Scholar
- 25 : Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model. Urology2001; 58: 141. Google Scholar
- 26 : Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol2002; 20: 4559. Google Scholar
- 27 : Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res2003; 9: 802. Google Scholar
- 28 : The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma. J Urol2008; 179: 61. Link, Google Scholar
- 29 : Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer2008; 123: 395. Google Scholar
- 30 : Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease. Cancer2009; 115: 235. Google Scholar
Department of Urology, Tokyo Medical University, Tokyo, Japan
